Elanco Animal Health (NYSE:ELAN) Issues FY25 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $0.80-$0.86 for the period, compared to the consensus estimate of $0.89. The company issued revenue guidance of $4.445-$4.510 billion, compared to the consensus revenue estimate of $4.52 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Elanco Animal Health Price Performance

Shares of ELAN stock traded down $0.60 during trading hours on Tuesday, hitting $10.51. 4,621,139 shares of the company’s stock were exchanged, compared to its average volume of 4,672,827. Elanco Animal Health has a 52 week low of $10.20 and a 52 week high of $18.80. The stock has a market cap of $5.20 billion, a price-to-earnings ratio of 26.28, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock’s 50-day moving average is $11.78 and its 200-day moving average is $13.09.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the company earned $0.08 EPS. The firm’s revenue was down 1.4% compared to the same quarter last year. As a group, research analysts forecast that Elanco Animal Health will post 0.91 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Barclays increased their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. UBS Group began coverage on Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 price target on the stock. Leerink Partners assumed coverage on Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective for the company. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley dropped their price target on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 29th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $16.00.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.